CGMs Are the New Executive Status Wearable. The Data May Mislead You.

A round white sensor, roughly the size of a poker chip, is now visible on the back of arms in Scarsdale gyms and Greenwich boardrooms alike. It belongs to Abbott's Lingo or Dexcom's Stelo, two continuous glucose monitors sold over the counter with no prescription required.

Neither wearer has diabetes. Both are treating glucose variability as the next executive optimization metric, following HRV and sleep scores.

Endocrinologists and published reviews describe a gap between that behavior and the evidence. Healthy people already spend nearly all their time in a normal range, and consumer apps were not built with that population's baseline in mind.

From Diabetes Tool to Boardroom Accessory

CGMs were built for one job: helping people with diabetes avoid dangerous highs and lows without finger-stick testing. Abbott and Dexcom spent a decade proving the devices to regulators for that exact purpose.

That changed in 2024, when Dexcom's Stelo became the first over-the-counter CGM cleared by the FDA. Abbott's Lingo followed with a direct-to-consumer rollout of its own.

Both companies now market past the diabetic population entirely. Marketing copy talks about energy crashes, focus, and metabolic performance rather than disease management.

That reframing lines up with an existing executive habit. A device that measures something internal and turns it into a number to optimize fits the same appetite that made Whoop and Oura status objects.

Abbott Lingo vs. Dexcom Stelo vs. Levels: What Each One Actually Is

The three names circulating in wellness conversation are not equivalent products. Two are sensors. One is an app.

The table below separates what each measures, what it costs, and whether a prescription is required.

Levels does not manufacture a sensor of its own. It licenses data from Abbott and Dexcom hardware and layers scoring, food logs, and coaching on top.

That distinction matters for the pushback below. The interpretation layer, not the sensor itself, is where most endocrinologists direct their skepticism.

What Endocrinologists Are Actually Saying

Published reviews of CGM use in non-diabetic people describe evidence that is thinner than the marketing suggests. A systematic review of CGM use for cardiovascular prevention in non-diabetic individuals concluded that direct evidence of a real cardiovascular benefit remains limited, even though glycemic variability looks like a meaningful surrogate marker on paper.

The same review noted that most benefit shown so far comes through indirect measures, like motivation and behavior change, rather than proven outcomes.

That is a narrower claim than "glucose monitoring works for healthy people." It is closer to: the tool might help some people act differently, but nobody has proven it prevents disease in someone who is not already at risk.

Clinical guidance for reading a CGM curve, meanwhile, was written for people managing an existing diagnosis. A healthy user gets the same graph with none of the clinical context that graph was designed to support.

A Normal Spike Is Not a Warning Sign

Blood sugar rises after most meals in every person, diabetic or not. It typically returns to baseline within about two hours.

That rise is not disease. It's digestion.

A consumer app has no way to know that context on its own. It flags a rise past a threshold the same way whether the person is diabetic, prediabetic, or simply ate rice for lunch.

For someone already anxious about food, weight, or performance, a red alert on a phone screen carries weight regardless of what the underlying number means. Clinicians have raised exactly this concern for people prone to restrictive eating patterns.

A device meant to inform can start to dictate. That's the trade the marketing rarely mentions.

Why the Optimization Instinct Buys In Anyway

Executives who already track HRV, sleep stages, and recovery scores are primed to add one more metric. A glucose number slots easily into a dashboard that already exists.

It also carries a visible marker other wearables lack. A sensor patch shows through a rolled sleeve in a way a ring or wristband does not always announce itself.

That visibility does real work in a peer group where discipline is currency. Wearing the sensor signals a level of self-management before anyone reads a single data point.

The signal, in other words, may matter more than the reading it's attached to.

Who a CGM Genuinely Helps

None of this means every non-diabetic user is wasting money. People with prediabetic labs, a strong family history of diabetes, or existing metabolic risk factors are a different case.

For that group, a focused trial paired with professional coaching has a real clinical rationale behind it. The distinction is between a short diagnostic trial and an indefinite, unsupervised optimization habit.

A healthy 42-year-old with no risk factors reading a graph every day is not the population the clinical literature was built around. That gap is the whole story here.

See our related coverage on the best HRV monitor for high-pressure jobs. Also read how quiet cracking is showing up in workforce wearable data. For subscription math on the broader wearable category, see the real 3-year cost of Whoop and Oura.

Next Move

Watch what happens to the underlying glycemic variability data as more healthy users log years, not weeks, on these apps. If large-scale non-diabetic datasets eventually show real predictive value, that changes the calculus for everyone currently guessing.

Until then, treat a spike alert the way you'd treat a single data point from any other new instrument. Ask what it would take to prove it means something, not just whether the app says it does.

If a reading is driving daily anxiety rather than an occasional adjustment, that's a signal about the tool, not the metabolism wearing it.

Last updated September 2026. Not medical, legal, or financial advice. This article is editorial commentary on consumer wearable marketing and published research.

It's not a recommendation to buy, avoid, or discontinue any specific device. Consult a physician before starting or interpreting continuous glucose monitoring, especially if you have a history of disordered eating.